Boston Scientific Corporation (NYSE:BSX) on Wednesday reported first-quarter 2025 revenues of $4.66 billion, beating the consensus estimate of $4.57 billion.

Sales increased 20.9% on a reported basis, compared to the company’s guidance range of 17%-19%, and 22.2% on an operational basis, 18.2% on an organic basis, compared to the company’s guidance range of 14%-16%.

The company earned an adjusted EPS of 75 cents, beating the consensus of 67 cents and exceeding the management guidance of 66-68 cents.

Also Read: Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry

The company’s cardiovascular segment generated sales of $3.09 billion, rising 26.2% (27.6% operationally and 25.6% organically). Boston Scientific reported a 29.8% growth in cardiology products to $2.43 billion and 14.4% in peripheral interventions, with sales of $656 million.

MedSurg segment revenues of $1.58 billion increased by 11.7% (12.8% operationally and 25.6% organically). Urology led the way with a 23.5% increase with sales of $633 million. Neuromodulation sales increased 5.8% to $271 million, and Endoscopy sales increased 4.7% to $673 million.

“We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio,” said Mike Mahoney, chairman and chief executive officer of Boston Scientific. “We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term.”

CFO Transition: Boston Scientific on Wednesday announced that Dan Brennan, executive vice president and CFO, will retire after nearly 30 years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025. 

Jon Monson, currently senior vice president, Investor Relations will succeed Brennan as executive vice president and CFO, effective June 30.

Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10%-12%, respectively.

The company estimates 2025 adjusted EPS of $2.87-$2.94 compared to prior guidance of $2.80-$2.87 and the consensus of $2.86.

The company estimates second quarter 2025 net sales growth of approximately 17.5%-19.5% on a reported basis and approximately 13%-15% on an organic basis, with adjusted EPS of 71-73 cents compared to consensus of 71 cents.

In March,  Boston Scientific agreed to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS Intravascular Ultrasound System.

Boston Scientific currently holds an equity stake of approximately 10%. Therefore, the transaction consists of an upfront payment of approximately $360 million for the 90% and up to $180 million upon achievement of a regulatory milestone.

Price Action: BSX stock is up 6.12% at $100.87 at the last check on Wednesday.

Read Next:

• Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence

Photo via Shutterstock